KalshiVérifier la disponibilitéKYC requis2% de fraisDonnées de résolution vérifiéesAssez bien calibréProbabilité implicite actuelle
Before 2028 92%En tête parmi 5 options
Qualité du marché
46 / 100
Faible qualitéVolume 24h
—
Liquidité
7,2 k €
Liquidité moyenneÉcart
5.0 pt
Spread modéréDonnées du marché
Mis à jour il y a 10 minutes
16 mai 26, 02:30 UTC1 janv. 27, 04:59 UTC
Tendances
Marchés Associés
Questions liées pour le contexte, et non une comparaison de contrats équivalents.
When will Compass Pathways submit a NDA for COMP360 psilocybin?
Kalshi[ACX 2026] Will the FDA approve a psilocybin treatment during 2026?
Manifold MarketsWill the FDA approve a psilocybin treatment during 2026?
FutuurWill the FDA approve any psychedelic substance for medical use this year?
KalshiWill the FDA approve a psychedelic-assisted therapy for a mental disorder by 2027?
Manifold MarketsWill the FDA approve intismeran autogene (V940/mRNA-4157)?
KalshiRègles
If the FDA approves COMP360 Psilocybin for Treatment-Resistant Depression for marketing the named outcome, then the market resolves to Yes.
- If the FDA approves COMP360 Psilocybin for Treatment-Resistant Depression for marketing before Jul 1, 2027, then the market resolves to Yes.
- If the FDA approves COMP360 Psilocybin for Treatment-Resistant Depression for marketing before Oct 1, 2027, then the market resolves to Yes.
- If the FDA approves COMP360 Psilocybin for Treatment-Resistant Depression for marketing before Jan 1, 2028, then the market resolves to Yes.
Marchés ouverts
Health & Medicine
POLYMARKETHantavirus pandemic in 2026?
- No+0.4pt97%
- Yes-0.4pt3%
- Volume total
- 15,7 M €
- Volume 24h
- 52,2 k €
KALSHIMeasles cases in 2026?
- Above 4000+2.0pt99%
- Above 300099%
- Above 600061%
+2 résultats de plus
- Volume total
- 870,4 k €
- Volume 24h
- 2,1 k €
POLYMARKETNew pandemic in 2026?
- No-1.0pt93.1%
- Yes+1.0pt6.9%
- Volume total
- 922,5 k €
- Volume 24h
- 1,8 k €
KALSHICyclosporiasis cases reported in the US in 2026?
- Above 18k99%
- Above 6k99%
- Above 10k99%
+12 résultats de plus
- Volume total
- 32,4 k €
- Volume 24h
- 1,3 k €
KALSHIWill WHO declare Hantavirus a Public Health Emergency of International Concern this Year?
- No97%
- Yes+0.4pt3%
- Volume total
- 1,6 M €
- Volume 24h
- 933,9 €
KALSHIHealthcare AI adoption in September
- Above 43%87%
- Above 43.75%59%
- Above 45%14%
+4 résultats de plus
- Volume total
- 810,1 €
- Volume 24h
- 767 €
- FDA decision: Ivonescimab by Summit Therapeutics (in 2026)
- Measles cases in U.S. in 2026?
- Measles cases in U.S. by September 30?
- What will the average number of measles cases be during Trump's term?
- When will Beam Therapeutics submit a BLA for Risto-cel?
- Will the FDA approve any psychedelic substance for medical use this year?
- Pandemic in 2026?
- How many human screwworm cases will be reported in the United States in 2026?
- When will Heidi Overton be confirmed as Commissioner of the FDA?
- Which countries will have an Ebola case in 2026?
- Ebola: new country confirmed before October 1?
Questions fréquentes
- Quelles sont les probabilités actuelles pour When will the FDA approve Compass Pathways' COMP360 Psilocybin? ?
- Kalshi cote Before 2028 à 92% au 11 septembre 2026.
- Quand When will the FDA approve Compass Pathways' COMP360 Psilocybin? sera-t-il résolu ?
- When will the FDA approve Compass Pathways' COMP360 Psilocybin? doit être résolu le 1 janvier 2027.
- Comment When will the FDA approve Compass Pathways' COMP360 Psilocybin? est-il réglé ?
- Kalshi règle ce marché comme suit : If the FDA approves COMP360 Psilocybin for Treatment-Resistant Depression for marketing the named outcome, then the market resolves to Yes.